Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Celadon Pharmaceuticals PLC ( (GB:CEL) ) just unveiled an update.
Celadon Pharmaceuticals Plc is currently facing financial challenges and is in urgent need of securing funds to continue operations. The company is engaged with a new finance provider who has completed due diligence and is expected to provide the necessary funds. However, if funding is not secured soon, the company may be placed into administration. In parallel, Celadon plans to cancel the trading of its ordinary shares on AIM if funding is secured. The company’s Annual General Meeting is scheduled for 30 June 2025, but a resolution to approve the company’s report and accounts will not be presented.
More about Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company specializing in the development, production, and sale of cannabis-based medicines. The company focuses on improving the quality of life for chronic pain sufferers and exploring treatments for conditions like autism. Celadon operates a 100,000 sq. ft EU-GMP approved facility in the UK, which includes indoor hydroponic cultivation, proprietary GMP extraction, and an R&D laboratory. The company holds a Home Office license for the commercial supply of pharmaceutical-grade cannabis products and is involved in a clinical trial for treating chronic pain. Additionally, Celadon has a minority interest in Kingdom Therapeutics, which is developing a cannabinoid medicine for Autism Spectrum Disorder.
Average Trading Volume: 223,273
Technical Sentiment Signal: Sell
Current Market Cap: £10.33M
For an in-depth examination of CEL stock, go to TipRanks’ Stock Analysis page.